
  
    
      
        Background_NNP
        Parkinson_NNP 's_POS disease_NN (_( PD_NNP )_) is_VBZ the_DT prevalent_JJ
        neurodegenerative_JJ disorder_NN of_IN adults_NNS and_CC is_VBZ believed_VBN to_TO be_VB
        due_JJ to_TO a_DT dopamine_NN deficiency_NN state_NN in_IN the_DT fore_NN brain_NN area_NN ._.
        It_PRP is_VBZ caused_VBN by_IN the_DT death_NN of_IN more_JJR then_RB 75_CD %_NN of_IN mid_JJ brain_NN
        dopamine_NN producing_VBG neurons_NNS ._. Tremor_NNP ,_, rigidity_NN ,_, and_CC akinesia_NN
        characterize_VBP the_DT disease_NN ._. Genetic_NNP and_CC environmental_JJ factors_NNS
        are_VBP believed_VBN to_TO initiate_VB Parkinson_NNP disease_NN ._. The_DT
        environmental_JJ theory_NN of_IN PD_NNP recently_RB received_VBD strong_JJ support_NN
        from_IN the_DT work_NN of_IN Greenamyre_NNP 
        et_CC al_NN ._. [_NN 1_CD ]_NN ._.
        At_IN present_JJ there_EX is_VBZ no_DT satisfactory_JJ medication_NN for_IN the_DT
        treatment_NN of_IN PD_NNP ._. Levodopa_NNP ,_, which_WDT is_VBZ a_DT dopamine_NN structural_JJ
        analog_NN is_VBZ the_DT "_'' golden_JJ standard_JJ "_'' in_IN PD_NNP ,_, but_CC its_PRP$ side_NN effects_NNS
        upon_IN long_JJ term_NN administration_NN (_( dyskinesia_NN ,_, dystonia_NN ,_, etc_FW ,_, [_NN
        2_CD ]_NN )_) compel_VB the_DT search_NN for_IN drugs_NNS with_IN better_RBR
        pharmacological_JJ profiles_NNS ._. Other_JJ dopamine_NN (_( DA_NNP )_) agonists_NNS do_VBP
        not_RB provide_VB adequate_JJ therapeutical_JJ response_NN [_NN 3_CD ]_NN ._. Thus_RB ,_,
        multidrug_NN therapy_NN is_VBZ usually_RB often_RB used_VBN ._. In_IN this_DT therapy_NN
        various_JJ adjuvants_NNS alleviate_VB side_NN effects_NNS of_IN levodopa_NN and_CC
        enhance_VB its_PRP$ antiparkinsonian_NN action_NN ._. Three_CD main_JJ groups_NNS of_IN
        compounds_NNS were_VBD found_VBN to_TO have_VB antiparkinson_NN effect_NN ._. These_DT
        are_VBP dopamine_NN (_( DA_NNP )_) receptor_NN agonists_NNS ,_, MAO-B_NNP inhibitors_NNS ,_, and_CC
        N-M_NNP ethyl-_NN D-A_NNP spartate_NN (_( NMDA_NNP )_) receptor_NN antagonists_NNS [_NN 4_CD ]_NN
        ._.
        The_DT monoamine_NN oxidase_NN enzyme_NN exists_VBZ under_IN two_CD forms_NNS ,_,
        MAO-A_NNP and_CC MAO-B_NNP ._. Dopamine_NNP is_VBZ oxidized_JJ in_IN the_DT brain_NN by_IN the_DT
        MAO-B_NNP form_NN ._. MAO-B_NNP inhibitors_NNS maintain_VBP dopamine_NN
        concentration_NN by_IN blocking_VBG the_DT MAO-B_NNP enzyme_NN ,_, whose_WP$ activity_NN
        is_VBZ also_RB known_VBN to_TO increase_VB with_IN age_NN [_NN 5_CD ]_NN ._. In_IN addition_NN ,_,
        MAO-B_NNP inhibitors_NNS can_MD block_VB the_DT formation_NN of_IN toxic_JJ
        metabolites_NNS from_IN the_DT compounds_NNS that_WDT are_VBP capable_JJ to_TO cause_VB PD_NNP
        (_( e_SYM ._. g_SYM ._. MPTP_NNP [_NN 1_CD ]_NN )_) ._.
        The_DT beneficial_JJ action_NN of_IN DA_NNP agonists_NNS is_VBZ based_VBN on_IN direct_JJ
        stimulation_NN of_IN the_DT DA_NNP receptors_NNS ._. There_EX are_VBP two_CD classes_NNS of_IN
        dopamine_NN receptors_NNS :_: D_NNP 1_CD (_( D_NNP 1_CD ,_, D_NNP 5_CD subtypes_NNS )_) and_CC D_NNP 2_CD (_( D_NNP 2_CD ,_, D_NNP 3_CD ,_, D_NNP 4_CD
        subtypes_NNS )_) ._. The_DT antiparkinson_NN action_NN of_IN dopamine_NN agonists_NNS
        was_VBD found_VBN to_TO be_VB mainly_RB due_JJ to_TO the_DT stimulation_NN of_IN the_DT
        D_NNP 2_CD -_: class_NN receptors_NNS [_NN 6_CD ]_NN ._. Therefore_RB we_PRP favored_VBD in_IN the_DT
        present_JJ work_NN those_DT DA_NNP agonists_NNS that_WDT exhibit_NN at_IN least_JJS
        moderate_JJ activity_NN toward_IN D_NNP 2_CD -_: class_NN of_IN DA_NNP receptors_NNS ._.
        NMDA_NNP antagonists_NNS were_VBD observed_VBN to_TO enhance_VB the_DT
        therapeutic_JJ effects_NNS of_IN dopaminomimetics_NNS in_IN PD_NNP ._. They_PRP block_VBP
        the_DT glutamatergic_JJ (_( excitatory_NN )_) pathways_NNS that_WDT are_VBP
        overstimulated_JJ in_IN PD_NNP [_NN 7_CD ]_NN ._. Such_JJ action_NN decreases_VBZ the_DT
        influx_NN of_IN calcium_NN ions_NNS into_IN the_DT neuron_NN ,_, and_CC hence_RB
        downregulates_NNS the_DT activation_NN of_IN calcium_NN dependent_JJ enzymes_NNS ._.
        This_DT can_MD prevent_VB the_DT neuronal_NN excitotoxic_JJ damage_NN ._.
        We_PRP set_VBD to_TO identify_VB the_DT pharmacophores_NNS responsible_JJ for_IN
        each_DT of_IN these_DT pharmacological_JJ activities_NNS so_RB as_IN to_TO provide_VB
        guidelines_NNS for_IN the_DT synthesis_NN of_IN new_JJ and_CC possibly_RB more_RBR
        potent_JJ analogues_NNS ._. We_PRP also_RB speculated_VBD that_IN better_JJR drugs_NNS
        could_MD be_VB identified_VBN that_WDT contain_VBP more_JJR than_IN one_CD biophore_NN ,_,
        possibly_RB providing_VBG activity_NN at_IN multiple_JJ sites_NNS ._. We_PRP therefore_RB
        designed_VBD some_DT potential_JJ drug_NN by_IN grouping_VBG several_JJ biophores_NNS
        into_IN a_DT single_JJ molecule_NN ,_, thereby_RB creating_VBG a_DT single_JJ molecule_NN
        cocktail_NN of_IN drug_NN activity_NN ._.
        The_DT use_NN of_IN such_JJ a_DT drug_NN might_MD reduce_VB side_NN effects_NNS stress_VBP
        imposed_VBN on_IN the_DT patients_NNS ,_, while_IN the_DT synergy_NN of_IN its_PRP$ effects_NNS
        might_MD improve_VB overall_JJ response_NN ._.
      
      
        Methods_NNP
        Information_NNP about_IN available_JJ MAO-B_NNP inhibitors_NNS [_NN 8_CD 9_CD 10_CD 11_CD
        ]_NN ,_, DA_NNP agonists_NNS [_NN 12_CD 13_CD 14_CD 15_CD ]_NN ,_, and_CC NMDA_NNP antagonists_NNS [_NN 16_CD
        17_CD 18_CD 19_CD 38_CD 39_CD 40_CD ]_NN was_VBD collected_VBN from_IN literature_NN sources_NNS ._.
        Their_PRP$ structures_NNS were_VBD coded_VBN and_CC three_CD separate_JJ databases_NNS
        (_( MAO_NNP inhibitors_NNS ,_, DA_NNP agonists_NNS ,_, and_CC NMDA_NNP antagonists_NNS )_) were_VBD
        created_VBN and_CC submitted_VBN to_TO analysis_NN by_IN the_DT MCASE_NNP program_NN ._.
        MCASE_NNP is_VBZ a_DT powerful_JJ analysis_NN tool_NN ,_, whose_WP$ principles_NNS have_VBP
        been_VBN described_VBN in_IN detail_NN elsewhere_RB [_NN 20_CD ]_NN ._. Basically_RB the_DT
        program_NN works_VBZ with_IN databases_NNS of_IN structurally_RB diverse_JJ
        compounds_NNS ,_, where_WRB each_DT entry_NN contains_VBZ the_DT structural_JJ formula_NN
        of_IN a_DT molecule_NN and_CC its_PRP$ activity_NN in_IN a_DT specific_JJ endpoint_NN ._.
        MCASE_NNP looks_VBZ for_IN key-features_JJ that_WDT may_MD be_VB responsible_JJ for_IN
        the_DT observed_VBN activity_NN of_IN the_DT compounds_NNS of_IN the_DT database_NN ._. The_DT
        basic_JJ idea_NN is_VBZ that_IN if_IN a_DT substructure_NN is_VBZ related_VBN to_TO the_DT
        observed_VBN activity_NN ,_, it_PRP will_MD be_VB found_VBN mainly_RB in_IN active_JJ and_CC
        marginally_RB active_JJ compounds_NNS ._. On_IN the_DT other_JJ hand_NN ,_, if_IN it_PRP is_VBZ
        not_RB relevant_JJ to_TO the_DT observed_VBN activity_NN ,_, it_PRP will_MD be_VB randomly_RB
        distributed_VBN amongst_IN active_JJ and_CC inactive_JJ compounds_NNS of_IN the_DT
        database_NN ._. The_DT substructures_NNS that_WDT are_VBP seen_VBN to_TO be_VB responsible_JJ
        for_IN activity_NN are_VBP called_VBN 
        biophores_NNS [_NN 20_CD ]_NN ,_, which_WDT in_IN the_DT case_NN
        of_IN pharmacological_JJ process_NN are_VBP basically_RB the_DT
        pharmacophores_NNS ._.
        The_DT compiled_VBN databases_NNS contain_VBP qualitative_JJ data_NNS about_IN
        compounds_NNS ._. Our_PRP$ MAO_NNP inhibitors_NNS database_NN used_VBD data_NNS from_IN
        Kalgutkar_NNP [_NN 8_CD ]_NN and_CC others_NNS ._. It_PRP consists_VBZ of_IN compounds_NNS tested_VBN
        as_IN potential_JJ MAO_NNP inhibitors_NNS ._. Two_CD strategies_NNS were_VBD tried_VBN with_IN
        this_DT database_NN ._. In_IN the_DT first_JJ approach_NN ,_, the_DT selectivity_NN of_IN
        MAO-inhibitors_NNP was_VBD used_VBN as_IN the_DT main_JJ criterion_NN (_( "_'' Selectivity_NNP
        database_NN "_'' )_) ._. Hence_RB ,_, the_DT preferable_JJ MAO-B_NNP inhibitors_NNS were_VBD
        treated_VBN as_IN "_'' actives_NNS "_'' ,_, while_IN MAO-A_NNP inhibitors_NNS where_WRB entered_VBD
        as_IN "_'' inactives_NNS "_'' ,_, and_CC unselective_JJ MAO_NNP inhibitors_NNS as_IN compounds_NNS
        of_IN "_'' marginal_JJ activity_NN "_'' ._. In_IN the_DT second_JJ strategy_NN ,_, only_RB the_DT
        actual_JJ activity_NN of_IN inhibitors_NNS towards_IN MAO-B_NNP form_NN was_VBD
        considered_VBN (_( "_'' Activity_NN database_NN "_'' )_) ._. Under_IN these_DT conditions_NNS
        all_DT compounds_NNS that_WDT inhibit_VBP the_DT MAO-B_NNP enzyme_NN were_VBD treated_VBN as_IN
        "_'' active_JJ "_'' and_CC the_DT others_NNS as_IN "_'' inactive_JJ "_'' ._. More_JJR details_NNS will_MD be_VB
        given_VBN later_RB during_IN the_DT discussion_NN of_IN the_DT specific_JJ databases_NNS
        and_CC their_PRP$ biophores_NNS ._.
        For_IN the_DT DA_NNP database_NN obtained_VBN from_IN the_DT paper_NN by_IN Seeman_NNP [_NN
        12_CD ]_NN and_CC others_NNS ,_, agonists_NNS are_VBP listed_VBN as_IN "_'' active_JJ "_'' ,_, while_IN
        antagonists_NNS are_VBP entered_VBN as_IN "_'' inactive_JJ "_'' ._. Partial_NNP agonists_NNS are_VBP
        seen_VBN as_IN compounds_NNS with_IN "_'' marginal_JJ activity_NN "_'' ._.
        The_DT third_JJ database_NN contains_VBZ information_NN about_IN NMDA_NNP
        antagonists_NNS and_CC includes_VBZ compounds_NNS collected_VBN from_IN various_JJ
        reports_NNS (_( [_NN 16_CD 21_CD ]_NN and_CC others_NNS )_) ._. The_DT database_NN was_VBD created_VBN
        as_IN follows_VBZ :_: NMDA_NNP antagonists_NNS were_VBD set_VBN as_IN "_'' actives_NNS "_'' ,_, NMDA_NNP
        agonists_NNS as_IN "_'' inactives_NNS "_'' and_CC partial_JJ agonists_NNS as_IN "_'' marginally_RB
        actives_NNS "_'' ._.
        In_IN addition_NN ,_, to_TO ensure_VB that_IN databases_NNS built_VBN on_IN the_DT bases_NNS
        of_IN selectivity_NN also_RB possess_VBP structural_JJ information_NN about_IN
        the_DT corresponding_JJ generic_JJ activities_NNS (_( binding_VBG to_TO the_DT NMDA_NNP
        or_CC DA_NNP receptors_NNS ,_, inhibiting_VBG both_DT MAO_NNP isoforms_NNS )_) ,_, active_JJ
        compounds_NNS were_VBD required_VBN to_TO have_VB low_JJ K_NNP 
        i_NNP (_( the_DT dissociation_NN constant_JJ of_IN the_DT
        molecule-receptor_JJ (_( enzyme_NN )_) complex_JJ )_) ._.
        Models_NNP were_VBD created_VBN automatically_RB by_IN the_DT MCASE_NNP program_NN
        for_IN each_DT of_IN these_DT databases_NNS ._. These_DT models_NNS were_VBD tested_VBN for_IN
        robustness_NNS and_CC reliability_NN ._. In_IN order_NN to_TO estimate_VB the_DT
        quality_NN of_IN the_DT models_NNS "_'' ten-off_JJ validation_NN procedures_NNS were_VBD
        performed_VBN for_IN each_DT database_NN ._. In_IN these_DT validation_NN
        procedures_NNS ,_, ninety_CD percents_NNS of_IN all_DT compounds_NNS from_IN a_DT
        database_NN were_VBD selected_VBN randomly_RB and_CC used_VBN as_IN learning_VBG set_VBN to_TO
        create_VB a_DT "_'' reduced_VBN "_'' model_NN ._. The_DT remaining_VBG ten_CD percents_NNS of_IN
        molecules_NNS (_( "_'' test_NN set_VBN "_'' )_) were_VBD then_RB tested_VBN against_IN the_DT reduced_VBN
        sets_NNS to_TO evaluated_VBD the_DT predictive_JJ power_NN of_IN these_DT models_NNS ._.
        Three_CD trials_NNS often-off_JJ validations_NNS were_VBD performed_VBN for_IN each_DT
        database_NN ._. The_DT results_NNS are_VBP shown_VBN in_IN Table_NNP 1_CD ._.
        As_IN can_MD be_VB seen_VBN ,_, good_JJ predictions_NNS ,_, i_NNP ._. e_SYM ._. high_JJ concordance_NN
        and_CC wide_JJ coverage_NN (_( almost_RB all_DT chemicals_NNS from_IN the_DT test_NN sets_NNS
        received_VBD a_DT prediction_NN )_) were_VBD obtained_VBN for_IN all_DT databases_NNS ._. The_DT
        ability_NN to_TO recognize_VB active_JJ compounds_NNS was_VBD slightly_RB better_JJR
        (_( by_IN about_IN 5_CD %_NN )_) for_IN the_DT DA_NNP database_NN ,_, whereas_IN for_IN the_DT MAO-B_NNP
        and_CC the_DT NMDA_NNP databases_NNS the_DT situation_NN was_VBD reversed_VBN ._. In_IN fact_NN ,_,
        we_PRP prefer_VBP to_TO underpredict_NN activity_NN (_( i_NNP ._. e_SYM ._. some_DT
        experimentally_RB active_JJ molecules_NNS being_VBG predicted_VBN to_TO be_VB
        inactive_JJ )_) rather_RB than_IN overpredict_NN it_PRP (_( when_WRB some_DT
        experimentally_RB inactive_JJ molecules_NNS are_VBP predicted_VBN to_TO be_VB
        active_JJ )_) ,_, since_IN overprediction_NN can_MD lead_VB to_TO the_DT design_NN of_IN
        drug_NN candidates_NNS that_WDT lack_NN efficacy_NN ._. Overall_RB ,_, high_JJ coverage_NN
        and_CC good_JJ predictive_JJ power_NN by_IN all_DT models_NNS indicated_VBD that_IN the_DT
        database_NN 's_POS biophores_NNS are_VBP not_RB products_NNS of_IN
        chance-correlation_JJ ,_, but_CC are_VBP relevant_JJ to_TO the_DT specific_JJ
        activity_NN types_NNS they_PRP represent_VBP ._.
        As_IN an_DT additional_JJ validation_NN ,_, each_DT model_NN was_VBD tested_VBN with_IN
        a_DT large_JJ group_NN of_IN structurally_RB diverse_JJ molecules_NNS ,_, which_WDT were_VBD
        taken_VBN from_IN the_DT FDA_NNP rodent_NN carcinogenicity_NN database_NN [_NN 35_CD ]_NN ._.
        Results_NNS (_( Table_NNP 2_LS )_) demonstrate_VB good_JJ specificity_NN of_IN the_DT
        models_NNS ._. Number_NNP of_IN predicted_VBD "_'' active_JJ "_'' compounds_NNS with_IN
        unaccounted_JJ activity_NN is_VBZ low_JJ (_( approximately_RB 1_CD %_NN for_IN the_DT NMDA_NNP
        and_CC DA_NNP database_NN and_CC even_RB less_JJR for_IN the_DT MAO-B_NNP databases_NNS )_) ._.
        The_DT most_RBS reliable_JJ biophores_NNS from_IN each_DT model_NN were_VBD then_RB
        selected_VBN as_IN initial_JJ structural_JJ elements_NNS for_IN the_DT
        construction_NN of_IN new_JJ drug_NN prototypes_NNS ._.
      
      
        Results_NNS
        
          MAO-B_NNP inhibitors_NNS
          IC_NNP 
          50_CD ,_, the_DT concentration_NN of_IN inhibitor_NN
          that_IN decreases_NNS enzyme_NN activity_NN by_IN 50_CD %_NN ,_, does_VBZ not_RB provide_VB
          sufficient_JJ mechanistic_JJ information_NN as_IN it_PRP depends_VBZ on_IN the_DT
          conditions_NNS of_IN the_DT experiment_NN [_NN 8_CD ]_NN ._. Therefore_RB it_PRP cannot_NN
          be_VB used_VBN to_TO compare_VB mechanistically_RB diverse_JJ data_NNS as_IN in_IN our_PRP$
          case_NN ._. Instead_RB ,_, we_PRP used_VBD K_NNP 
          i_NNP ,_, the_DT dissociation_NN constant_JJ of_IN the_DT
          enzyme-inhibitor_JJ complex_NN ,_, to_TO compare_VB the_DT activity_NN of_IN
          different_JJ inhibitors_NNS ._. Indeed_RB ,_, this_DT is_VBZ a_DT better_JJR indicator_NN
          of_IN a_DT molecule_NN 's_POS potential_JJ to_TO reversibly_RB inhibit_VB the_DT
          enzyme_NN ._. Furthermore_RB reversible_JJ inhibitors_NNS are_VBP less_RBR likely_JJ
          to_TO cause_VB enzyme_NN malfunction_NN [_NN 8_CD ]_NN than_IN irreversible_JJ
          ones_NNS ._.
          As_IN mentioned_VBN earlier_RBR the_DT selective_JJ and_CC reversible_JJ
          inhibition_NN of_IN MAO-B_NNP versus_CC that_IN of_IN MAO-A_NNP is_VBZ the_DT major_JJ
          criterion_NN used_VBN to_TO create_VB the_DT "_'' Selectivity_NNP database_NN "_''
          (_( Table_NNP 1_LS )_) ._. Chemicals_NNS with_IN a_DT ratio_NN greater_JJR than_IN 10_CD were_VBD
          considered_VBN to_TO be_VB selective_JJ MAO-B_NNP inhibitors_NNS and_CC therefore_RB
          were_VBD used_VBN as_IN "_'' active_JJ "_'' entries_NNS ,_, while_IN compounds_NNS with_IN a_DT
          ratio_NN less_JJR than_IN 0_CD ._. 1_CD were_VBD considered_VBN to_TO be_VB selective_JJ MAO-A_NNP
          inhibitors_NNS and_CC thus_RB "_'' inactive_JJ "_'' ._. MAO_NNP inhibitors_NNS which_WDT
          ratio_NN was_VBD within_IN 0_CD ._. 1_CD -_: 10_CD range_NN were_VBD considered_VBN as_IN
          unselective_JJ MAO-B_NNP inhibitors_NNS and_CC were_VBD treated_VBN as_IN
          "_'' marginally_RB active_JJ "_'' molecules_NNS ._.
          In_IN the_DT "_'' Activity_NN database_NN "_'' (_( Table_NNP 1_LS )_) ,_, inhibitors_NNS with_IN
          a_DT K_NNP 
          i_NNP (_( MAO-B_NNP )_) value_NN less_JJR than_IN 1_CD μM_NN were_VBD
          treated_VBN as_IN "_'' active_JJ "_'' ,_, while_IN compounds_NNS with_IN a_DT K_NNP 
          i_NNP (_( MAO-B_NNP )_) value_NN in_IN the_DT 1_CD -_: 5_CD μM_NN range_NN
          were_VBD treated_VBN as_IN "_'' marginally_RB active_JJ "_'' molecules_NNS ._. All_DT those_DT
          with_IN a_DT K_NNP 
          i_NNP (_( MAO-B_NNP )_) larger_JJR than_IN 5_CD μM_NN were_VBD
          entered_VBN as_IN "_'' inactive_JJ "_'' ._.
          •_NN The_DT best_JJS biophores_NNS (_( Table_NNP 3_LS )_) to_TO be_VB used_VBN for_IN the_DT
          derivation_NN of_IN new_JJ and_CC better_JJR drugs_NNS were_VBD selected_VBN from_IN the_DT
          MAO_NNP datasets_NNS on_IN the_DT base_NN of_IN the_DT following_JJ criteria_NNS :_:
          •_NN The_DT biophore_NN should_MD have_VB a_DT high_JJ probability_NN to_TO be_VB
          relevant_JJ to_TO activity_NN (_( PRA_NNP )_) ._. The_DT lowest_JJS acceptable_JJ PRA_NNP
          value_NN was_VBD 75_CD %_NN ._.
          A_DT sufficient_JJ number_NN of_IN molecules_NNS should_MD contain_VB the_DT
          selected_VBN biophore_NN ._. The_DT biophore_NN should_MD be_VB present_JJ in_IN at_IN
          least_JJS 10_CD compounds_NNS ._.
          Analysis_NNP of_IN biophores_NNS #_# 1_CD ,_, #_# 2_CD (_( #_# 4_CD ,_, #_# 5_LS )_) showed_VBD that_IN both_DT
          of_IN them_PRP occur_VBP in_IN substituted_VBN 5_CD -_: [_NN 4_CD -_: (_( benzyloxy_NN )_)
          phenyl_NN ]_NN -_: 1_CD ,_, 3_CD ,_, 4_CD -_: oxadiazol-_NN 2_CD -_: (_( 3_CD H_NNP )_) -_: ones_NNS and_CC their_PRP$ analogs_NNS
          (_( Figure_NN 1_LS )_) ,_, many_JJ of_IN which_WDT are_VBP known_VBN to_TO be_VB strong_JJ MAO-B_NNP
          inhibitors_NNS [_NN 9_CD ]_NN ._. Biophore_NNP #_# 2_CD represents_VBZ a_DT flexible_JJ -_: CH_NNP 
          2_CD O-_NNP bridge_NN between_IN aryl_NN moieties_NNS and_CC
          was_VBD found_VBN to_TO enhance_VB the_DT activity_NN and_CC selectivity_NN of_IN the_DT
          inhibitors_NNS as_IN shown_VBN in_IN the_DT original_JJ work_NN [_NN 9_CD ]_NN ._.
          Biophores_NNP #_# 1_CD and_CC #_# 2_CD include_VBP aromatic_JJ moieties_NNS ,_, whose_WP$ main_JJ
          function_NN is_VBZ presumably_RB to_TO bind_NN to_TO the_DT hydrophobic_JJ site_NN of_IN
          MAO_NNP ._.
          Biophore_NNP #_# 3_CD (_( #_# 6_CD )_) exists_VBZ in_IN N-_NNP (_( 2_CD -_: Aminoethyl_NNP )_) -_: benzamides_NNS
          with_IN substitutions_NNS on_IN the_DT aryl_NN ring_NN ._. These_DT compounds_NNS are_VBP
          known_VBN to_TO be_VB time-dependent_JJ inhibitors_NNS of_IN MAO-B_NNP [_NN 22_CD ]_NN
          ._.
          Several_JJ QSAR_NNP and_CC CoMFA_NNP analyses_NNS were_VBD published_VBN ,_,
          reporting_VBG relevant_JJ properties_NNS and_CC structural_JJ parameters_NNS
          that_WDT govern_VBP MAO_NNP inhibition_NN [_NN 23_CD 24_CD 25_CD 26_CD ]_NN ._. All_DT of_IN them_PRP
          were_VBD performed_VBN for_IN narrow_JJ data_NNS sets_NNS and_CC hence_RB the_DT results_NNS
          were_VBD confined_VBN to_TO the_DT same_JJ group_NN of_IN compounds_NNS ._. We_PRP used_VBD
          these_DT studies_NNS to_TO confirm_VB the_DT relevance_NN of_IN some_DT of_IN our_PRP$
          biophores_NNS ._. For_IN example_NN ,_, biophore_NN #_# 2_CD was_VBD found_VBN to_TO be_VB an_DT
          important_JJ factor_NN enhancing_VBG the_DT interaction_NN between_IN the_DT
          inhibitor_NN and_CC the_DT protein_NN core_NN of_IN the_DT MAO_NNP enzyme_NN [_NN 23_CD 25_CD
          27_CD ]_NN ._.
        
        
          NMDA_NNP antagonists_NNS
          The_DT NMDA_NNP receptor_NN consists_VBZ of_IN two_CD subunits_NNS that_WDT
          together_RB create_VB a_DT membrane_NN channel_NN ._. Each_DT subunit_NN belongs_VBZ
          to_TO the_DT NR_NNP 1_CD or_CC NR_NNP 2_CD subunit_NN family_NN ._. Various_JJ splice_NN variants_NNS
          are_VBP also_RB known_VBN [_NN 16_CD ]_NN ._. Activation_NNP of_IN the_DT NMDA_NNP channel_NN
          requires_VBZ that_DT glutamate_NN and_CC glycine_NN bind_NN at_IN the_DT same_JJ time_NN
          to_TO NR_NNP 2_CD and_CC NR_NNP 1_CD subunits_NNS respectively_RB ._. Thus_RB ,_, three_CD main_JJ
          types_NNS of_IN NMDA_NNP antagonists_NNS are_VBP known_VBN :_: glycine-site_JJ
          antagonists_NNS (_( binds_NNS to_TO NR_NNP 1_CD subunits_NNS )_) ,_, glutamate-site_JJ
          antagonists_NNS (_( binds_NNS to_TO NR_NNP 2_CD subunits_NNS )_) and_CC channel-blockers_JJ ._.
          In_IN order_NN to_TO avoid_VB unwanted_JJ side_NN effects_NNS ,_, NMDA_NNP antagonists_NNS
          should_MD have_VB either_CC low_JJ affinity_NN for_IN the_DT NMDA_NNP receptor_NN
          (_( e_SYM ._. g_SYM ._. amino-adamantane_JJ derivatives_NNS )_) or_CC bind_NN with_IN high_JJ
          selectivity_NN to_TO one_CD type_NN of_IN NMDA_NNP receptor_NN (_( e_SYM ._. g_SYM ._.
          ifenprodil_NN ,_, eliprodil_NN ,_, or_CC similar_JJ compounds_NNS )_) [_NN 16_CD ]_NN ._.
          The_DT chemicals_NNS used_VBN in_IN the_DT NMDA_NNP database_NN were_VBD required_VBN
          to_TO have_VB significant_JJ affinity_NN for_IN the_DT NMDA_NNP receptor_NN ._. For_IN
          that_DT purpose_NN ,_, K_NNP 
          i_NNP (_( the_DT dissociation_NN constant_JJ of_IN the_DT
          molecule-receptor_JJ complex_JJ )_) of_IN accepted_VBD NMDA_NNP antagonists_NNS
          was_VBD required_VBN to_TO be_VB less_JJR than_IN 5_CD μM_NN ._. The_DT same_JJ criteria_NNS were_VBD
          used_VBN in_IN the_DT selection_NN of_IN the_DT best_JJS biophores_NNS from_IN the_DT NMDA_NNP
          model_NN as_IN were_VBD described_VBN in_IN the_DT case_NN of_IN the_DT MAO_NNP databases_NNS
          (_( Biophores_NNP #_# 7_CD -_: 10_CD ,_, Table_NNP 3_LS )_) ._.
          Biophore_NNP #_# 7_CD features_NNS the_DT glutamate-binding_JJ site_NN of_IN
          NMDA_NNP antagonists_NNS (_( Figure_NN 2_LS )_) ._. The_DT molecules_NNS that_WDT contain_VBP
          it_PRP are_VBP derivatized_JJ amino_JJ acids_NNS ,_, whose_WP$ phosphonate_NN group_NN
          is_VBZ a_DT functional_JJ replacement_NN of_IN the_DT γ-carboxyl_JJ group_NN of_IN
          glutamic_JJ acid_NN ._. The_DT phosphonate_NN group_NN of_IN the_DT NMDA_NNP
          antagonist_NN binds_NNS to_TO the_DT glutamate-receptor_JJ ,_, as_IN does_VBZ the_DT
          natural_JJ agonist_NN glutamic_JJ acid_NN ,_, but_CC no_DT conformational_NN
          change_NN that_IN activates_NNS the_DT NMDA_NNP channel_NN occurs_VBZ [_NN 28_CD ]_NN ._.
          Beart_NNP et_CC al_NN [_NN 21_CD ]_NN performed_VBD a_DT SAR_NNP analysis_NN of_IN this_DT type_NN
          of_IN NMDA_NNP antagonists_NNS ._. They_PRP report_VBP a_DT deep_JJ hydrophobic_JJ
          pocket_NN (_( good_JJ for_IN binding_VBG of_IN the_DT class_NN of_IN compounds_NNS shown_VBN
          in_IN Figure_NN 3_CD B_NNP )_) and_CC a_DT region_NN to_TO accommodate_VB the_DT
          ω-phosphonate-group_JJ (_( biophore_NN #_# 7_CD binding_JJ site_NN )_) [_NN 21_CD ]_NN as_IN
          structural-features_JJ of_IN the_DT binding_JJ site_NN of_IN NMDA_NNP
          competitive_JJ antagonists_NNS ._. The_DT generic_JJ structure_NN of_IN these_DT
          NMDA_NNP antagonists_NNS is_VBZ shown_VBN in_IN Figure_NN 2_CD ._.
          Biophores_NNP #_# 8_CD and_CC #_# 9_CD are_VBP characteristic_NN of_IN the_DT NMDA_NNP
          channel_NN blockers_NNS ._. Biophore_NNP #_# 8_CD features_NNS an_DT aromatic_JJ
          residue_NN that_IN presumably_RB binds_NNS to_TO the_DT hydrophobic_JJ pockets_NNS
          of_IN the_DT channel_NN walls_NNS (_( e_SYM ._. g_SYM ._. Triptophan-_NNP 593_CD ,_, Alanine-_NNP 627_CD [_NN
          29_CD ]_NN )_) ._. The_DT nitrogen_NN of_IN biophore_NN #_# 9_CD can_MD contribute_VB to_TO
          activity_NN possibly_RB by_IN interacting_VBG with_IN the_DT negatively_RB
          charged_VBN residues_NNS or_CC by_IN forming_VBG hydrogen_NN bonds_NNS (_( e_SYM ._. g_SYM ._.
          Asparagine-_NNP 598_CD [_NN 29_CD ]_NN )_) ._.
          Figure_NN 3_CD A_DT )_) shows_VBZ the_DT generic_JJ structure_NN of_IN an_DT NMDA_NNP
          antagonist_NN that_WDT carries_VBZ biophores_NNS #_# 8_CD and_CC #_# 9_CD and_CC B_NNP )_) the_DT
          relative_JJ locations_NNS of_IN biophores_NNS #_# 8_CD ,_, #_# 9_CD and_CC #_# 10_CD in_IN the_DT
          eliprodil_NN molecular_JJ family_NN ._. Biophores_NNP #_# 8_CD ,_, #_# 9_CD ,_, and_CC #_# 10_CD
          also_RB occur_VB in_IN the_DT NMDA_NNP antagonists_NNS that_WDT bind_NN to_TO
          glutamate-binding_JJ site_NN of_IN NMDA_NNP receptor_NN (_( e_SYM ._. g_SYM ._. #_# 8_CD in_IN SDZ_NNP
          EAB_NNP 515_CD ,_, #_# 9_CD in_IN SDZ_NNP EAA_NNP 494_CD ,_, #_# 10_CD in_IN SDZ_NNP 220_CD -_: 581_CD ,_, [_NN 21_CD 37_CD ]_NN
          )_) ._.
          Thus_RB the_DT NMDA_NNP biophores_NNS that_WDT were_VBD identified_VBN actually_RB
          characterize_VB two_CD groups_NNS of_IN NMDA_NNP antagonists_NNS :_: channel_NN
          blockers_NNS and_CC glutamate-site_JJ antagonists_NNS ._.
        
        
          Dopamine_NNP agonists_NNS
          The_DT same_JJ strategy_NN was_VBD used_VBN to_TO create_VB the_DT Dopamine_NNP
          agonists_NNS database_NN as_IN was_VBD used_VBN for_IN the_DT NMDA_NNP database_NN ._.
          Compounds_NNP with_IN substantial_JJ affinity_NN for_IN dopamine_NN
          receptors_NNS (_( K_NNP 
          i_NNP within_IN nanomolar_NN range_NN )_) were_VBD
          collected_VBN ._. The_DT best_JJS biophores_NNS were_VBD selected_VBN using_VBG the_DT
          same_JJ criteria_NNS as_IN those_DT used_VBN to_TO assess_VB the_DT NMDA_NNP and_CC the_DT
          MAO_NNP databases_NNS (_( Table_NNP 3_CD #_# 11_CD -_: 16_CD )_) ._.
          Biophore_NNP #_# 12_CD identifies_VBZ the_DT ortho_NN hydroxyl_NN groups_NNS of_IN
          the_DT catechol_NN ring_NN ,_, which_WDT is_VBZ one_CD of_IN the_DT structural_JJ
          features_NNS of_IN dopamine_NN and_CC its_PRP$ derivatives_NNS ._. Biophore_NNP #_# 11_CD
          describes_VBZ agonists_NNS that_WDT possess_VBP only_RB one_CD hydroxyl_NN ,_, in_IN
          meta-position_JJ (_( preclamol_NN ,_, RU-_NNP 24213_CD ,_, RU-_NNP 24926_CD ,_, etc_FW )_) ._. This_DT
          biophore_NN demonstrates_VBZ the_DT relative_JJ importance_NN of_IN the_DT
          meta-hydroxyl_JJ group_NN as_IN compared_VBN to_TO the_DT para-hydroxyl_JJ
          group_NN ._. For_IN example_NN meta-tyramine_JJ 's_POS binding_JJ affinity_NN to_TO
          the_DT dopamine_NN receptor_NN is_VBZ significantly_RB greater_JJR than_IN that_DT
          of_IN para-tyramine_JJ [_NN 30_CD ]_NN ._.
          Biophores_NNP #_# 14_CD and_CC #_# 15_CD characterize_VB DA_NNP agonists_NNS without_IN
          hydroxyl_NN groups_NNS in_IN the_DT aromatic_JJ ring_NN ._. Putatively_NNP ,_, the_DT
          aromatic_JJ nitrogen_NN of_IN this_DT biophore_NN carries_VBZ the_DT function_NN
          of_IN the_DT meta-hydroxyl_JJ group_NN since_IN it_PRP has_VBZ the_DT same_JJ
          structural_JJ location_NN relatively_RB to_TO the_DT phenylethylamine_NN
          backbone_NN ._.
          Most_JJS of_IN the_DT compounds_NNS that_WDT contain_VBP biophore_NN #_# 13_CD (_( 9_CD out_IN
          of_IN 12_CD active_JJ compounds_NNS )_) also_RB carry_VB a_DT hydroxyl_NN group_NN
          (_( Table_NNP 3_LS )_) ._. The_DT majority_NN of_IN compounds_NNS that_WDT contain_VBP
          biophore_NN #_# 16_CD also_RB have_VBP at_IN least_JJS one_CD hydroxyl_NN in_IN one_CD of_IN
          the_DT three_CD possible_JJ branching_VBG positions_NNS (_( Table_NNP 3_LS )_) ._.
          Metabolites_NNP of_IN such_JJ compounds_NNS might_MD be_VB more_RBR active_JJ than_IN
          the_DT parent_NN compound_NN ._. Thus_RB ,_, aromatic_JJ hydroxylation_NN of_IN such_JJ
          compounds_NNS at_IN the_DT ortho-position_JJ would_MD form_VB a_DT catechol_NN
          ring_NN (_( Table_NNP 3_CD ,_, #_# 12_CD )_) and_CC produce_VB metabolites_NNS that_WDT are_VBP
          structural_JJ analogues_NNS to_TO dopamine_NN ._.
          Both_DT biophores_NNS #_# 13_CD and_CC #_# 16_CD represent_VB dopamine-like_JJ
          agonists_NNS that_WDT have_VBP restricted_VBN conformation_NN for_IN the_DT sake_NN
          of_IN enhanced_VBN binding_JJ ._.
          Based_VBN on_IN the_DT biophores_NNS that_WDT were_VBD identified_VBN by_IN the_DT
          program_NN ,_, a_DT generic_JJ structure_NN of_IN the_DT DA_NNP agonist_NN was_VBD
          constructed_VBN (_( Figure_NN 4_LS )_) ._. The_DT specifications_NNS for_IN such_JJ
          structure_NN include_VBP a_DT nitrogen_NN atom_NN separated_VBN by_IN two_CD carbon_NN
          atoms_NNS from_IN an_DT aromatic_JJ moiety_NN and_CC containing_VBG an_DT electron_NN
          donating_VBG substituent_NN at_IN the_DT meta-position_JJ ._. The_DT importance_NN
          of_IN this_DT backbone_NN finds_VBZ support_NN in_IN a_DT number_NN of_IN QSAR_NNP and_CC
          CoMFA_NNP analyses_NNS as_RB well_RB [_NN 30_CD 31_CD ]_NN ._.
          To_TO ensure_VB compatibility_NN we_PRP compared_VBD biophores_NNS and_CC
          biophobes_NNS (_( fragments_NNS that_WDT are_VBP found_VBN to_TO be_VB responsible_JJ for_IN
          molecular_JJ inactivity_NN )_) across_IN all_DT three_CD databases_NNS and_CC
          found_VBD no_DT collisions_NNS ._. On_IN the_DT contrary_JJ ,_, structural_JJ overlap_VB
          between_IN some_DT biophores_NNS across_IN the_DT three_CD databases_NNS was_VBD
          observed_VBN ._. This_DT was_VBD used_VBN as_IN an_DT additional_JJ encouragement_NN to_TO
          select_VB them_PRP for_IN inclusion_NN in_IN prospective_JJ new_JJ drugs_NNS ._.
        
      
      
        Discussion_NNP
        The_DT modeling_NN procedure_NN requires_VBZ the_DT construction_NN of_IN
        precursor_NN candidates_NNS (_( precursor_NN here_RB is_VBZ a_DT molecule_NN designed_VBN
        to_TO have_VB a_DT single_JJ mechanism_NN of_IN antiparkinsonian_NN action_NN )_) on_IN
        the_DT basis_NN of_IN selected_VBN and_CC compatible_JJ biophores_NNS of_IN each_DT
        database_NN ._. Precursor_NNP candidates_NNS for_IN NMDA_NNP antagonism_NN ,_, MAO-B_NNP
        inhibition_NN and_CC DA_NNP agonism_NN were_VBD drawn_VBN to_TO be_VB within_IN the_DT
        context_NN of_IN the_DT types_NNS of_IN molecules_NNS they_PRP are_VBP derived_VBN from_IN ._.
        The_DT precursor_NN structures_NNS that_WDT were_VBD generated_VBN were_VBD then_RB
        merged_VBN into_IN candidate_NN drug_NN molecules_NNS ._.
        Two_CD types_NNS of_IN precursors_NNS of_IN active_JJ MAO-B_NNP inhibitors_NNS were_VBD
        identified_VBN ._. The_DT structure_NN of_IN the_DT first_JJ one_CD is_VBZ shown_VBN in_IN
        Figure_NN 1_CD (_( 1_CD Aand_NNP 1_CD B_NNP )_) as_IN a_DT generic_JJ moiety_NN ._. The_DT second_JJ one_CD is_VBZ
        based_VBN on_IN a_DT class_NN of_IN compounds_NNS that_WDT contain_VBP biophore_NN #_# 3_CD ,_,
        whose_WP$ structure_NN is_VBZ shown_VBN in_IN Table_NNP 3_CD (_( Biophore_NNP #_# 3_LS )_) ._. The_DT
        latter_JJ precursor_NN has_VBZ the_DT advantage_NN of_IN small_JJ size_NN and_CC its_PRP$
        activity_NN is_VBZ quite_RB tolerant_NN to_TO derivatization_NN at_IN the_DT
        para-position_JJ [_NN 22_CD ]_NN ,_, whereas_IN the_DT former_NN is_VBZ known_VBN to_TO have_VB
        high_JJ oral_JJ bioavailability_NN and_CC low_JJ toxic_JJ effects_NNS in_IN rats_NNS [_NN 9_CD
        ]_NN ._.
        A_DT possible_JJ way_NN of_IN derivatization_NN of_IN the_DT compound_NN in_IN
        Figure_NN 1_CD (_( X_NNP =_SYM O_NNP ,_, Z_NNP =_SYM CN_NNP ,_, R_NN =_SYM H_NNP )_) is_VBZ substitution_NN at_IN the_DT
        terminal_NN aromatic_JJ ring_NN ._. Analysis_NNP of_IN the_DT original_JJ work_NN [_NN 9_CD ]_NN
        shows_VBZ that_IN such_JJ substitution_NN decreases_NNS binding_JJ affinity_NN ._.
        However_RB ,_, the_DT decrease_NN in_IN activity_NN is_VBZ acceptable_JJ for_IN methyl_NN
        and_CC methoxyl_NN substitutions_NNS in_IN meta-_NN and_CC para-positions_JJ ._.
        Thus_RB ,_, the_DT IC_NNP 
        50_CD of_IN the_DT unsubstituted_JJ compound_NN is_VBZ 2_CD ._. 2_CD
        nM_NN ,_, whereas_IN the_DT meta-methylated_JJ analog_NN has_VBZ an_DT IC_NNP 
        50_CD of_IN 8_CD nM_NN ;_: the_DT value_NN for_IN the_DT
        para-methylated_JJ is_VBZ 15_CD nM_NN ,_, that_IN of_IN the_DT para-methoxylated_JJ is_VBZ
        27_CD nM_NN ,_, and_CC the_DT IC_NNP 
        50_CD of_IN the_DT meta-methoxylated_JJ derivative_NN
        is_VBZ 29_CD nM_NN [_NN 9_CD ]_NN ._.
        There_EX are_VBP many_JJ possible_JJ choices_NNS for_IN the_DT selection_NN of_IN a_DT
        suitable_JJ structure_NN for_IN an_DT NMDA_NNP antagonist_NN ._. One_CD possibilitys_NNS
        to_TO use_VB the_DT backbone_NN presented_VBN in_IN Figure_NN 3_CD A_DT ;_: another_DT one_CD is_VBZ
        to_TO use_VB the_DT generic_JJ structure_NN of_IN the_DT glutamate-site_JJ NMDA_NNP
        antagonists_NNS (_( Figure_NN 2_CD B_NNP )_) ._. The_DT latter_JJ group_NN contains_VBZ fewer_JJR
        biophores_NNS ,_, but_CC there_EX are_VBP some_DT insights_NNS of_IN its_PRP$ mechanism_NN of_IN
        action_NN and_CC a_DT structural_JJ analysis_NN has_VBZ been_VBN made_VBN for_IN it_PRP [_NN 21_CD
        ]_NN ._. Hence_RB ,_, glutamate-site_JJ NMDA_NNP antagonists_NNS (_( Figure_NN 2_CD B_NNP )_) were_VBD
        favored_VBN as_IN a_DT structural_JJ prototype_NN since_IN some_DT NMDA_NNP
        antagonists_NNS from_IN the_DT former_JJ group_NN (_( Figure_NN 3_CD A_DT )_) express_VB
        antagonistic_JJ activity_NN toward_IN dopamine_NN receptors_NNS (_( e_SYM ._. g_SYM ._.
        haloperidol_NN )_) ._.
        Glutamate-site_NNP NMDA_NNP antagonists_NNS can_MD be_VB readily_RB
        derivitized_JJ ._. Thus_RB the_DT aryl_NN ring_NN (_( Figure_NN 2_CD B_NNP )_) can_MD carry_VB quite_RB
        a_DT large_JJ variety_NN of_IN substituents_NNS that_WDT enhance_VB binding_JJ if_IN
        they_PRP are_VBP hydrophobic_JJ [_NN 21_CD ]_NN ._. Since_IN many_JJ good_JJ biophores_NNS
        were_VBD identified_VBN in_IN the_DT DA_NNP database_NN we_PRP designed_VBD two_CD
        different_JJ DA_NNP precursors_NNS (_( Figure_NN 5_LS )_) instead_RB of_IN one_CD ._. This_DT was_VBD
        accomplished_VBN by_IN combining_VBG a_DT few_JJ biophores_NNS into_IN a_DT single_JJ
        molecule_NN ._. Each_DT of_IN these_DT precursors_NNS has_VBZ structurally_RB close_VB
        known_VBN homologues_NNS that_WDT are_VBP potent_JJ D_NNP 2_CD -_: type_NN dopamine_NN
        agonists_NNS ._.
        When_WRB merged_VBD together_RB in_IN different_JJ ways_NNS ,_, the_DT prototype_NN
        structures_NNS yielded_VBD a_DT group_NN of_IN candidates_NNS ._. These_DT compounds_NNS
        were_VBD tested_VBN "_'' in_IN silico_NN "_'' against_IN all_DT compiled_VBN databases_NNS (_( DA_NNP ,_,
        MAO_NNP ,_, and_CC NMDA_NNP )_) ._. Candidates_NNP with_IN the_DT best_JJS predictions_NNS were_VBD
        submitted_VBN for_IN further_JJ evaluation_NN of_IN their_PRP$ pharmacokinetic_JJ
        parameters_NNS ._. Thus_RB ,_, they_PRP were_VBD tested_VBN against_IN databases_NNS
        predicting_VBG plasma_NN protein_NN binding_JJ affinity_NN [_NN 32_CD ]_NN ,_, oral_JJ
        bioavailability_NN and_CC urine_NN excretion_NN (_( unpublished_JJ results_NNS )_) ._.
        The_DT metabolism_NN of_IN each_DT candidate_NN was_VBD then_RB evaluated_VBN by_IN the_DT
        META_NNP program_NN [_NN 33_CD ]_NN using_VBG a_DT mammal_NN metabolism_NN database_NN ._.
        LogP_NNP values_NNS (_( logarithm_NN of_IN the_DT n-octanol_JJ /_NN water_NN partition_NN
        coefficient_NN )_) were_VBD calculated_VBN by_IN the_DT MCASE_NNP program_NN on_IN the_DT
        base_NN of_IN a_DT group_NN contribution_NN approach_NN [_NN 34_CD ]_NN ._.
        Possible_JJ side_NN effects_NNS of_IN the_DT drug_NN candidates_NNS were_VBD
        assessed_VBN by_IN testing_VBG each_DT candidate_NN and_CC its_PRP$ predicted_VBD
        metabolites_NNS against_IN carcinogenicity_NN and_CC mutagenicity_NN
        databases_NNS [_NN 35_CD ]_NN ,_, [_NN 36_CD ]_NN ._.
        Evaluating_VBG candidate_NN molecules_NNS by_IN the_DT predicted_VBN
        pharmacokinetic_JJ parameters_NNS (_( Table_NNP 4_LS )_) we_PRP favored_VBD those_DT with_IN
        higher_JJR oral_JJ bioavailability_NN scores_NNS and_CC lower_JJR urine_NN
        excretion_NN scores_NNS ._. For_IN optimal_NN sustained_VBD action_NN ,_, we_PRP chose_VBD a_DT
        plasma_NN protein_NN binding_JJ range_NN of_IN 50_CD to_TO 90_CD percent_NN ._.
        The_DT four_CD finalists_NNS shown_VBN on_IN Figures_NNS 6_CD and_CC 7_CD received_VBD the_DT
        best_JJS overall_JJ prediction_NN ._. Compounds_NNP III_NNP with_IN X_NNP =_SYM O_NNP ,_, Y_NNP =_SYM H_NNP
        and_CC OH_NNP in_IN position_NN 1_CD ,_, and_CC compound_NN II_NNP with_IN X_NNP =_SYM S_NNP and_CC Y_NNP =_SYM H_NNP
        were_VBD selected_VBN as_IN the_DT most_RBS promising_JJ candidates_NNS since_IN their_PRP$
        predicted_VBD oral_JJ bioavailability_NN was_VBD among_IN the_DT highest_JJS while_IN
        the_DT potential_JJ harmful_JJ side_NN effects_NNS were_VBD predicted_VBN to_TO be_VB low_JJ
        (_( Table_NNP 4_LS )_) ._. Nevertheless_RB ,_, the_DT entire_JJ group_NN of_IN compounds_NNS is_VBZ
        proposed_VBN for_IN synthesis_NN and_CC evaluation_NN of_IN their_PRP$ potential_JJ
        antiparkinsonian_NN activity_NN ._. Structural_JJ variation_NN (_( changing_VBG
        X_NNP ,_, Y_NNP ,_, and_CC the_DT position_NN of_IN the_DT hydroxyl_NN group_NN )_) can_MD be_VB used_VBN
        for_IN membrane_NN permeability_NN adjustment_NN ,_, enhancement_NN of_IN oral_JJ
        bioavailability_NN and_CC improvement_NN of_IN Blood-_NNP Brain_NNP Barrier_NNP
        penetration_NN ._.
      
    
  
